Institution
Hebron University
Education•Hebron, Palestinian Territory•
About: Hebron University is a education organization based out in Hebron, Palestinian Territory. It is known for research contribution in the topics: Population & Cancer. The organization has 2714 authors who have published 4180 publications receiving 163736 citations.
Papers published on a yearly basis
Papers
More filters
TL;DR: In this paper, the authors outline how preclinical studies based on patient-derived models have informed the design of practice-changing clinical trials and integrate these experiences into a common framework to reshape the future design of biology-informed clinical trials.
Abstract: Remarkable progress has been made in the development of biomarker-driven targeted therapies for patients with multiple cancer types, including melanoma, breast and lung tumours, although precision oncology for patients with colorectal cancer (CRC) continues to lag behind. Nonetheless, the availability of patient-derived CRC models coupled with in vitro and in vivo pharmacological and functional analyses over the past decade has finally led to advances in the field. Gene-specific alterations are not the only determinants that can successfully direct the use of targeted therapy. Indeed, successful inhibition of BRAF or KRAS in metastatic CRCs driven by activating mutations in these genes requires combinations of drugs that inhibit the mutant protein while at the same time restraining adaptive resistance via CRC-specific EGFR-mediated feedback loops. The emerging paradigm is, therefore, that the intrinsic biology of CRC cells must be considered alongside the molecular profiles of individual tumours in order to successfully personalize treatment. In this Review, we outline how preclinical studies based on patient-derived models have informed the design of practice-changing clinical trials. The integration of these experiences into a common framework will reshape the future design of biology-informed clinical trials in this field.
84 citations
Duke University1, Hebron University2, Istituto Giannina Gaslini3, Utrecht University4, Vanderbilt University Medical Center5, University of Minnesota6, University Health System7, Cleveland Clinic8, Loyola University Medical Center9, Singapore General Hospital10, University of Turin11, Sheba Medical Center12
TL;DR: UCB expanded ex vivo with nicotinamide shortens median neutrophil recovery by 9.5 days and median platelet recovery by 12 days, establishing feasibility, safety, and efficacy of an ex vivo expanded UCB unit as a stand-alone graft.
Abstract: PurposeIncreasing the number of hematopoietic stem and progenitor cells within an umbilical cord blood (UCB) graft shortens the time to hematopoietic recovery after UCB transplantation. In this study, we assessed the safety and efficacy of a UCB graft that was expanded ex vivo in the presence of nicotinamide and transplanted after myeloablative conditioning as a stand-alone hematopoietic stem-cell graft.MethodsThirty-six patients with hematologic malignancies underwent transplantation at 11 sites.ResultsThe cumulative incidence of neutrophil engraftment at day 42 was 94%. Two patients experienced secondary graft failure attributable to viral infections. Hematopoietic recovery was compared with that observed in recipients of standard UCB transplantation as reported to the Center for International Blood and Marrow Transplant Research (n = 146). The median time to neutrophil recovery was 11.5 days (95% CI, 9 to 14 days) for recipients of nicotinamide-expanded UCB and 21 days (95% CI, 20 to 23 days) for the c...
84 citations
TL;DR: Mucosal healing is associated with a normalization of the perception of health by most IBD patients independently of treatment, however, a significant group of patients do not achieve restoration of HRQOL, which reinforces the necessity of a global care addressed to all patient concerns to achieve patients’ complete health restoration.
Abstract: BackgroundInflammatory bowel disease (IBD) is a debilitating immune disorder that impairs function and health-related quality of life (HRQOL). A goal of IBD treatment is mucosal healing, but it is not known whether it achieves normalization of the patients’ perception of health. This can be assessed
83 citations
TL;DR: Plasma levels of cytokeratin‐18 fragments are reliable noninvasive markers of AH and two thirds of TJLB can be avoided, which can be useful in centers where this technique is not readily available.
83 citations
TL;DR: The current status of targeted therapies in the treatment of EC and GC are described, which include EGFR inhibitors, antiangiogenic agents, cell cycle inhibitors, apoptosis promoters and matrix metalloproteinases inhibitors.
83 citations
Authors
Showing all 2723 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| José Baselga | 156 | 707 | 122498 |
| M. I. Martínez | 134 | 1251 | 79885 |
| Josep Tabernero | 111 | 803 | 68982 |
| Jordi Rello | 103 | 694 | 35994 |
| Xavier Montalban | 95 | 762 | 52842 |
| James M. Downey | 91 | 381 | 29506 |
| Enriqueta Felip | 83 | 622 | 53364 |
| Joaquim Bellmunt | 82 | 660 | 41472 |
| Joan Montaner | 80 | 489 | 22413 |
| Marc Miravitlles | 76 | 651 | 25671 |
| David H. Salat | 75 | 241 | 36779 |
| Eduard Gratacós | 75 | 531 | 20178 |
| Alex Rovira | 74 | 356 | 19586 |
| Ramon Bataller | 72 | 283 | 19316 |
| Maria Buti | 71 | 493 | 26596 |